Tags

Type your tag names separated by a space and hit enter

Bioavailability of vitamin D(2) and D(3) in healthy volunteers, a randomized placebo-controlled trial.
J Clin Endocrinol Metab. 2013 Nov; 98(11):4339-45.JC

Abstract

BACKGROUND

The bioequivalence of the different forms of vitamin D, ergocalciferol (vitamin D2) and cholecalciferol (vitamin D3), has been questioned. Earlier studies have suggested that vitamin D2 is less biologically active than vitamin D3.

OBJECTIVE AND DESIGN

In a parallel study, we tested the effects of supplementation with 50-μg/d doses of vitamin D2 or D3 or a placebo over a period of 8 weeks on 25(OH)D2, 25(OH)D3, their sum 25(OH)D (primary outcome variables), and PTH in healthy volunteers applying a double-blind, randomized study design. The study was conducted during the winter of 2012 in Halle (Saale), Germany, at latitude 51°47N, when UVB irradiation is virtually absent. Blood samples for the determinations of vitamin D status and PTH were collected at baseline and after 4 and 8 weeks of supplementation.

RESULTS

In the placebo group (n = 19), 25(OH)D3 decreased from 39.4 ± 14.2 to 31.1 ± 12.4 nmol/L after 8 weeks (P < .01). In the vitamin D3 group (n = 42), the concentrations of 25(OH)D3 increased from 41.5 ± 22.8 nmol/L at baseline to 88.0 ± 22.1 nmol/L after 8 weeks (P < .01). In the group receiving vitamin D2 (n = 46), the 25(OH)D2 concentrations increased significantly, whereas the 25(OH)D3 concentration fell from 36.4 ± 13.3 nmol/L at baseline to 16.6 ± 6.3 nmol/L after 8 weeks (P < .01). The total 25(OH)D was not different between the groups at baseline but differed significantly between the groups after 4 and 8 weeks (P < .001).

CONCLUSIONS

Vitamin D3 increases the total 25(OH)D concentration more than vitamin D2. Vitamin D2 supplementation was associated with a decrease in 25(OH)D3, which can explain the different effect on total 25(OH)D.

Authors+Show Affiliations

PhD, Department of Clinical Medicine, P.O. Box 7804, N-5020 Bergen, Norway. jutta.dierkes@med.uib.no.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24001747

Citation

Lehmann, Ulrike, et al. "Bioavailability of Vitamin D(2) and D(3) in Healthy Volunteers, a Randomized Placebo-controlled Trial." The Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 11, 2013, pp. 4339-45.
Lehmann U, Hirche F, Stangl GI, et al. Bioavailability of vitamin D(2) and D(3) in healthy volunteers, a randomized placebo-controlled trial. J Clin Endocrinol Metab. 2013;98(11):4339-45.
Lehmann, U., Hirche, F., Stangl, G. I., Hinz, K., Westphal, S., & Dierkes, J. (2013). Bioavailability of vitamin D(2) and D(3) in healthy volunteers, a randomized placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism, 98(11), 4339-45. https://doi.org/10.1210/jc.2012-4287
Lehmann U, et al. Bioavailability of Vitamin D(2) and D(3) in Healthy Volunteers, a Randomized Placebo-controlled Trial. J Clin Endocrinol Metab. 2013;98(11):4339-45. PubMed PMID: 24001747.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Bioavailability of vitamin D(2) and D(3) in healthy volunteers, a randomized placebo-controlled trial. AU - Lehmann,Ulrike, AU - Hirche,Frank, AU - Stangl,Gabriele I, AU - Hinz,Katja, AU - Westphal,Sabine, AU - Dierkes,Jutta, Y1 - 2013/09/03/ PY - 2013/9/5/entrez PY - 2013/9/5/pubmed PY - 2014/1/3/medline SP - 4339 EP - 45 JF - The Journal of clinical endocrinology and metabolism JO - J Clin Endocrinol Metab VL - 98 IS - 11 N2 - BACKGROUND: The bioequivalence of the different forms of vitamin D, ergocalciferol (vitamin D2) and cholecalciferol (vitamin D3), has been questioned. Earlier studies have suggested that vitamin D2 is less biologically active than vitamin D3. OBJECTIVE AND DESIGN: In a parallel study, we tested the effects of supplementation with 50-μg/d doses of vitamin D2 or D3 or a placebo over a period of 8 weeks on 25(OH)D2, 25(OH)D3, their sum 25(OH)D (primary outcome variables), and PTH in healthy volunteers applying a double-blind, randomized study design. The study was conducted during the winter of 2012 in Halle (Saale), Germany, at latitude 51°47N, when UVB irradiation is virtually absent. Blood samples for the determinations of vitamin D status and PTH were collected at baseline and after 4 and 8 weeks of supplementation. RESULTS: In the placebo group (n = 19), 25(OH)D3 decreased from 39.4 ± 14.2 to 31.1 ± 12.4 nmol/L after 8 weeks (P < .01). In the vitamin D3 group (n = 42), the concentrations of 25(OH)D3 increased from 41.5 ± 22.8 nmol/L at baseline to 88.0 ± 22.1 nmol/L after 8 weeks (P < .01). In the group receiving vitamin D2 (n = 46), the 25(OH)D2 concentrations increased significantly, whereas the 25(OH)D3 concentration fell from 36.4 ± 13.3 nmol/L at baseline to 16.6 ± 6.3 nmol/L after 8 weeks (P < .01). The total 25(OH)D was not different between the groups at baseline but differed significantly between the groups after 4 and 8 weeks (P < .001). CONCLUSIONS: Vitamin D3 increases the total 25(OH)D concentration more than vitamin D2. Vitamin D2 supplementation was associated with a decrease in 25(OH)D3, which can explain the different effect on total 25(OH)D. SN - 1945-7197 UR - https://www.unboundmedicine.com/medline/citation/24001747/Bioavailability_of_vitamin_D_2__and_D_3__in_healthy_volunteers_a_randomized_placebo_controlled_trial_ L2 - https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.2012-4287 DB - PRIME DP - Unbound Medicine ER -